Literature DB >> 32800596

Metabolic syndrome-related sarcopenia is associated with worse prognosis in patients with gastric cancer: A prospective study.

Li-Bin Xu1, Hui-Hui Zhang1, Ming-Ming Shi1, Ze-Xin Huang1, Wei-Teng Zhang2, Xiao-Dong Chen2, Yi-Qi Cai1, Guan-Bao Zhu3, Xian Shen4, Wen-Jing Chen5.   

Abstract

OBJECTIVES: Sarcopenia and metabolic syndrome (MetS) are associated with the prognosis from malignant tumors. However, evidence of the relationship between sarcopenia and MetS among gastric cancer (GC) patients following radical gastrectomy is lacking. This study assessed the association between preoperative sarcopenia and MetS among GC patients and analyzed the prognosis of patients with different malnutrition statuses.
METHODS: We prospectively assessed the preoperative statuses of sarcopenia and MetS among patients who underwent radical gastrectomy from July 2014 to December 2017. We combined sarcopenia and MetS to generate four groups: MetS-related sarcopenia group (MSS), sarcopenia group (S), MetS group (MS), and normal group (N).
RESULTS: A total of 749 patients with resectable GC were included in this study. Preoperative MetS was associated with sarcopenia (p < 0.001). Multivariate logistic regression presented that MetS-related sarcopenia (OR = 2.445; p = 0.010) and sarcopenia alone (OR = 2.117; p = 0.001) were independent predictors of grade Ⅱ and above complications, while MetS alone was not (p = 0.342). Cox regression analysis revealed that MetS-related sarcopenia led to the worst prognosis in the four groups (MSS vs MS: HR = 3.555, p < 0.001; MSS vs N: HR = 2.020, p = 0.003; MSS vs S: HR = 1.763, p = 0.021). However, the MetS group had better prognosis than the normal group (MS vs N: HR = 0.568, p = 0.048).
CONCLUSION: Preoperative MetS was associated with sarcopenia among GC patients. MetS-related sarcopenia resulted in a significantly worse prognosis. The long-term prognoses of patients with sarcopenia were impaired by preoperative MetS, while patients without sarcopenia benefited. Thus, patients with both sarcopenia and MetS require more medical interventions.
Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Gastric cancer; Metabolic syndrome; Prognosis; Sarcopenia

Mesh:

Year:  2020        PMID: 32800596     DOI: 10.1016/j.ejso.2020.07.032

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  2 in total

1.  A novel metabolism-related prognostic gene development and validation in gastric cancer.

Authors:  Xingxing Zhang; Xu Chen; Jiayun Liu; Yaqi Li; Jian Wu; Menglin Chen; Ruijuan Zhang; Xintian Xu; Tianyi Xu; Qingmin Sun
Journal:  Clin Transl Oncol       Date:  2022-09-27       Impact factor: 3.340

2.  Effect of Thyroid-Stimulating Hormone Suppression on Muscle Function After Total Thyroidectomy in Patients With Thyroid Cancer.

Authors:  Jun Choul Lee; Byong-Sop Song; Young Mi Kang; Yu-Ri Kim; Yea Eun Kang; Ju Hee Lee; Minho Shong; Hyon-Seung Yi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-10       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.